These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 29333729)

  • 41. Novel technologies and emerging biomarkers for personalized cancer immunotherapy.
    Yuan J; Hegde PS; Clynes R; Foukas PG; Harari A; Kleen TO; Kvistborg P; Maccalli C; Maecker HT; Page DB; Robins H; Song W; Stack EC; Wang E; Whiteside TL; Zhao Y; Zwierzina H; Butterfield LH; Fox BA
    J Immunother Cancer; 2016; 4():3. PubMed ID: 26788324
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Cancer immunotherapy by immuno-checkpoint blockade].
    Kawakami Y
    Rinsho Ketsueki; 2015 Oct; 56(10):2186-94. PubMed ID: 26458459
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nanotechnology synergized immunoengineering for cancer.
    Chauhan DS; Dhasmana A; Laskar P; Prasad R; Jain NK; Srivastava R; Jaggi M; Chauhan SC; Yallapu MM
    Eur J Pharm Biopharm; 2021 Jun; 163():72-101. PubMed ID: 33774162
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Emerging strategies to bypass transplant rejection via biomaterial-assisted immunoengineering: Insights from islets and beyond.
    Abbaszadeh S; Nosrati-Siahmazgi V; Musaie K; Rezaei S; Qahremani M; Xiao B; Santos HA; Shahbazi MA
    Adv Drug Deliv Rev; 2023 Sep; 200():115050. PubMed ID: 37549847
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Implantable and Injectable Biomaterial Scaffolds for Cancer Immunotherapy.
    Li J; Luo Y; Li B; Xia Y; Wang H; Fu C
    Front Bioeng Biotechnol; 2020; 8():612950. PubMed ID: 33330440
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
    Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Delivery strategies of cancer immunotherapy: recent advances and future perspectives.
    Zhao Z; Zheng L; Chen W; Weng W; Song J; Ji J
    J Hematol Oncol; 2019 Nov; 12(1):126. PubMed ID: 31779642
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
    Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Biomaterials-Mediated Engineering of the Immune System.
    Backlund C; Jalili-Firoozinezhad S; Kim B; Irvine DJ
    Annu Rev Immunol; 2023 Apr; 41():153-179. PubMed ID: 36696570
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunomodulatory metal-based biomaterials for cancer immunotherapy.
    Yuan K; Zhang C; Pan X; Hu B; Zhang J; Yang G
    J Control Release; 2024 Nov; 375():249-268. PubMed ID: 39260573
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Basics of cancer immunotherapy].
    Fujioka Y; Nishikawa H
    Rinsho Ketsueki; 2016; 57(11):2346-2354. PubMed ID: 27941285
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Advanced Biomaterials for Cell-Specific Modulation and Restore of Cancer Immunotherapy.
    Ruan S; Huang Y; He M; Gao H
    Adv Sci (Weinh); 2022 May; 9(16):e2200027. PubMed ID: 35343112
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Enhancing cancer immunotherapy with nanomedicine.
    Irvine DJ; Dane EL
    Nat Rev Immunol; 2020 May; 20(5):321-334. PubMed ID: 32005979
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Novel immunotherapies for hematologic malignancies.
    Nelson MH; Paulos CM
    Immunol Rev; 2015 Jan; 263(1):90-105. PubMed ID: 25510273
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Biomaterial-assisted photoimmunotherapy for cancer.
    Chen M; Chen Q
    Biomater Sci; 2020 Nov; 8(21):5846-5858. PubMed ID: 33016276
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Biomaterial-based platforms for modulating immune components against cancer and cancer stem cells.
    Desai N; Hasan U; K J; Mani R; Chauhan M; Basu SM; Giri J
    Acta Biomater; 2023 Apr; 161():1-36. PubMed ID: 36907233
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nanomaterials as Smart Immunomodulator Delivery System for Enhanced Cancer Therapy.
    Yuan C; Liu Y; Wang T; Sun M; Chen X
    ACS Biomater Sci Eng; 2020 Sep; 6(9):4774-4798. PubMed ID: 33455212
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combining nanomedicine and immune checkpoint therapy for cancer immunotherapy.
    Boone CE; Wang L; Gautam A; Newton IG; Steinmetz NF
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2022 Jan; 14(1):e1739. PubMed ID: 34296535
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cancer immunotherapies, their safety and toxicity.
    Alatrash G; Jakher H; Stafford PD; Mittendorf EA
    Expert Opin Drug Saf; 2013 Sep; 12(5):631-45. PubMed ID: 23668362
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Protein-Engineered Biomaterials for Cancer Theranostics.
    Liu X; Wang C; Liu Z
    Adv Healthc Mater; 2018 Oct; 7(20):e1800913. PubMed ID: 30260583
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.